Who entered the maintenance phase?
Of the 441 adults who started open-label tirzepatide, 378 qualified for randomization at week 60. They had lost at least 5% of baseline weight and tolerated at least 10 mg. The trial assigned 140 to continue their maximum tolerated dose of 10 mg or 15 mg, 144 to reduce to 5 mg, and 94 to switch to placebo for another 52 weeks.[1]
The evidence on lower-dose GLP-1 maintenance depends on which patients enter a study. SURMOUNT-MAINTAIN selected adults who had already lost weight and tolerated a higher dose, so the results apply most directly to patients who meet those conditions.
Weight change and rescue treatment
At week 112, the model estimated weight loss from the original baseline at 21.9% (95% CI 20.3% to 23.5%) on the maximum tolerated dose, 16.6% (95% CI 15.1% to 18.0%) on 5 mg, and 9.9% (95% CI 8.8% to 11.1%) on placebo. Both tirzepatide groups had greater weight loss from baseline than placebo.[1]
From week 84, 24 weeks after randomization, the protocol allowed rescue tirzepatide if participants regained more than half the weight they had lost. In the rescue analysis, 11 of 138 (8%) at the maximum tolerated dose, 35 of 142 (25%) at 5 mg, and 60 of 90 (67%) on placebo received it.[1]
Safety and funding
Gastrointestinal symptoms were the most common adverse events with tirzepatide and occurred mainly during dose escalation. Eli Lilly funded the trial and took part in the design, data collection, analysis, and preparation of the report.[1]